Anzeige
Erschienen in:
01.11.2010 | Letter to the Editor
Rapid recurrence of craniopharyngioma following recombinant human growth hormone replacement
Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2010
Einloggen, um Zugang zu erhaltenExcerpt
A 10-year-old boy was referred because of postoperative growth hormone deficiency (GHD) that occurred 5 years after initial complete resection of craniopharyngioma (CP). On admission, basal GH was 0.10 ng/ml and peak GH was 0.21 ng/ml after GH-releasing hormone plus arginine, which met the criteria for GHD. No residual changes were recognized on MRI scans obtained in 2007 (Fig. 1, middle panel), and we commenced recombinant human growth hormone (rhGH, somatotropin, 0.025 mg/kg/day) therapy. After 17 months of rhGH therapy, MRI scans revealed a large cystic mass in the suprasellar region (Fig. 1, right panel). The tumor was removed and diagnosed histologically as a CP, as before.
Fig. 1
Coronal MRI images are shown in the upper panel and transverse MRI images are shown in the lower panel. In 2002, MRI revealed a large cystic mass in the suprasellar region (left panel, gadolinium-enhanced T1 scan, arrows) and the tumor was resected (middle left panel, T1 scan). In April 2007, 5 years after the operation, no residual changes were detected by MRI (middle right panel, T2 scan). In October 2008, 17 months after the initiation of recombinant human growth hormone (somatotropin) therapy, MRI scans revealed a large cystic mass sized 5.2 × 4.0 × 3.4 cm (right panel, gadolinium-enhanced T1 scan, arrows)
× ![]()
…